Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

(1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-ץ-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18−20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50−0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66−0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20−22%] vs. 14% [95% CI 13−16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.

Citing Articles

Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn's and Colitis meeting.

Jun Y, Koh S, Myung D, Park S, Ooi C, Sood A Intest Res. 2023; 21(3):353-362.

PMID: 37533266 PMC: 10397552. DOI: 10.5217/ir.2023.00013.

References

Hsia E, Schluger N, Cush J, Chaisson R, Matteson E, Xu S . Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum. 2012; 64(7):2068-77. DOI: 10.1002/art.34382. View

Houben R, Dodd P . The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016; 13(10):e1002152. PMC: 5079585. DOI: 10.1371/journal.pmed.1002152. View

Hasan T, Au E, Chen S, Tong A, Wong G . Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open. 2018; 8(9):e022445. PMC: 6144320. DOI: 10.1136/bmjopen-2018-022445. View

Kumar P, Vuyyuru S, Kante B, Sahu P, Goyal S, Madhu D . Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Aliment Pharmacol Ther. 2022; 55(11):1431-1440. DOI: 10.1111/apt.16839. View

Fehily S, Al-Ani A, Abdelmalak J, Rentch C, Zhang E, Denholm J . Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022; 56(1):6-27. PMC: 9325436. DOI: 10.1111/apt.16952. View

Kleinert S, Tony H, Krueger K, Detert J, Mielke F, Rockwitz K . Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis. 2012; 71(11):1791-5. DOI: 10.1136/annrheumdis-2011-200941. View

Zabana Y, Domenech E, Lopez San Roman A, Beltran B, Cabriada J, Saro C . Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008; 14(10):1387-91. DOI: 10.1002/ibd.20496. View

Kucharzik T, Ellul P, Greuter T, Rahier J, Verstockt B, Abreu C . ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021; 15(6):879-913. DOI: 10.1093/ecco-jcc/jjab052. View

Arias-Guillen M, Riestra S, de Francisco R, Palacios J, Belda J, Escalante P . T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(2):329-38. DOI: 10.1097/01.MIB.0000438429.38423.62. View

10.

Zabana Y, Panes J, Nos P, Gomollon F, Esteve M, Garcia-Sanchez V . The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions. Gastroenterol Hepatol. 2020; 43(9):551-558. DOI: 10.1016/j.gastrohep.2020.05.007. View

11.

Obrador A, Lopez San Roman A, Munoz P, Fortun J, Gassull M . [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]. Gastroenterol Hepatol. 2003; 26(1):29-33. DOI: 10.1016/s0210-5705(03)70338-0. View

12.

Kedia S, Mouli V, Kamat N, Sankar J, Ananthakrishnan A, Makharia G . Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020; 115(3):340-349. DOI: 10.14309/ajg.0000000000000527. View

13.

Getahun H, Matteelli A, Chaisson R, Raviglione M . Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22):2127-35. DOI: 10.1056/NEJMra1405427. View

14.

Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A . Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. J Crohns Colitis. 2016; 10(10):1179-85. DOI: 10.1093/ecco-jcc/jjw129. View

15.

Riestra S, Taxonera C, Zabana Y, Carpio D, Beltran B, Manosa M . Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2020; 44(1):51-66. DOI: 10.1016/j.gastrohep.2020.04.006. View

16.

Carmona L, Gomez-Reino J, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Martin Mola E . Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52(6):1766-72. DOI: 10.1002/art.21043. View

17.

Carpio D, Jauregui-Amezaga A, De Francisco R, de Castro L, Barreiro-de Acosta M, Mendoza J . Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment. J Crohns Colitis. 2016; 10(10):1186-93. DOI: 10.1093/ecco-jcc/jjw022. View

18.

Keane J, Gershon S, Wise R, Kasznica J, Schwieterman W, Siegel J . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345(15):1098-104. DOI: 10.1056/NEJMoa011110. View

19.

Wong S, Gao Q, Tsoi K, Wu W, Tam L, Lee N . Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2015; 71(1):64-72. DOI: 10.1136/thoraxjnl-2015-207811. View

20.

Taxonera C, Ponferrada A, Bermejo F, Riestra S, Saro C, Martin-Arranz M . Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2017; 11(7):792-800. DOI: 10.1093/ecco-jcc/jjx022. View